A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular events in people with established CVD and overweight or obesity without ...

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College ...

This study was a prespecified secondary analysis of the SELECT trial, which was designed to determine the effect of semaglutide on total CV events in patients without diabetes aged ≥45 years ...

1,5 In this prespecified secondary analysis of the SELECT trial, semaglutide 2.4 mg reduced total events (first and subsequent) by 22% (MR 0.78; 95% CI 0.70–0.86; P<0.001), 1 reduced non-fatal ...

A recent analysis of data from the SELECT trial of semaglutide in overweight or obese patients found that the cardiovascular benefits of the drug seemed to accrue regardless of how much weight ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA ...

The STEP-HFpEF data have emerged shortly after semaglutide became the first drug in the category to reduce cardiovascular outcomes in the phase 3 SELECT trial, revealing that it reduced the risk ...

in semaglutide 2.4 mg users compared to non-users in a time-to-first event analysis. This differed from the SELECT trial, whereby the primary MACE composite endpoint comprised of non-fatal heart ...